madman
Super Moderator
Chapters
1:13 Dr. Heath's opening remarks
4:20 Prostate cancer statistics
7:49 Clinical states model
9:22 Risk stratification and staging workup
11:26 FDA approved agents
13:55 Androgen pathway
15:33 Androgen deprivation side effects
18:09 Overall survival benefit with intensification
20:16 Treatment selection factors
23:00 Clinical considerations
23:43 Disease burden and disease presentation
24:25 Clinical trial updates
25:30 Real-world treatment intensification patterns
26:10 Global data
26:44 Chemotherapy side effects
27:40 Chemotherapy fitness
29:03 Chemotherapy in castrate-resistant disease
29:38 Prostate cancer clinical trial updates
33:10 DNA damage repair pathways
33:40 PARP inhibitors
35:15 PARP inhibitor side effects
36:20 Genetic testing results
37:56 Microsatellite instability-high cancer
38:53 Immunotherapy in prostate cancer
39:28 Sipuleucel-T
41:30 Radium-223
42:26 Radium study and data
43:22 PSMA
49:45 Novel targets in clinical trials
50:16 Dr. Moyad and Dr. Heath Q&A
